Last updated: June 25, 2026
Azurity Pharmaceuticals, Inc. v. Zydus Worldwide DMCC (D.N.J.), case number 3:23-cv-04152, is a Hatch-Waxman patent litigation matter filed in 2023 in connection with Zydus seeking FDA approval for a competing product of Azurity’s branded drug. The case posture and substantive issues required to produce an accurate litigation summary, including asserted patents, filing/notice dates, drug/ANDA/BLA context, parties’ Orange Book positions, and any settlement or final judgment, are not provided in the prompt and cannot be reconstructed with sufficient precision without the underlying docket documents.
What is the litigation posture in AZURITY v. ZYDUS Worldwide DMCC (3:23-cv-04152)?
Answer: Not determinable from the information provided.
Docket essentials typically required for a complete posture summary
- Case filing date and court division (federal district and judge)
- Whether it is an ANDA Paragraph IV (or other FDA pathway)
- Status milestones
- pleadings stage
- Markman schedule and claim construction
- expert discovery
- summary judgment motions
- trial/bench decision
- Whether the case was dismissed, stayed, or resolved via settlement
Which patents does Azurity assert in AZURITY PHARMACEUTICALS, INC. v. ZYDUS WORLDWIDE DMCC 3:23-cv-04152?
Answer: Not determinable from the information provided.
What must be known to count and categorize asserted IP
- Asserted U.S. patents and their listed claims
- Patent expiration dates and PTA (patent term adjustment)
- Patent type split
- active ingredient composition
- formulation/composition
- method of use
- manufacturing/process
- polymorph/crystal form, salt, hydrate
- Whether each patent is “Orange Book” listed for the brand and with what NDA
What Paragraph IV triggers does 3:23-cv-04152 depend on?
Answer: Not determinable from the information provided.
Typical Paragraph IV mapping (needed for analysis)
- The ANDA number (or other FDA application)
- The Orange Book listed drug and NDA of the brand
- The specific Paragraph IV certification(s) in the ANDA
- The “carve-out” issue if fewer than all patents are challenged
What claims are Zydus accused of infringing?
Answer: Not determinable from the information provided.
Claim-level issues usually covered in a tight infringement analysis
- Direct infringement vs inducement/contributory theories
- Comparative claim charts structure
- Whether Zydus’s ANDA product is alleged to infringe
- as manufactured
- as used
- via a specific dose regimen
- Potential design-around positions
- different salt form
- different polymorph
- different excipient system
- different process parameters
What defenses and invalidity arguments are typically raised in cases like 3:23-cv-04152?
Answer: Not determinable from the information provided.
Invalidity categories that are usually evaluated (but require the actual pleadings)
- Non-infringement
- Invalidity under 35 U.S.C. §§ 101, 102, 103, 112
- Obviousness combinations for formulation/process claims
- Written description and enablement challenges
- Indefiniteness challenges
- Prosecution history estoppel and claim scope limits
Has the case been stayed, dismissed, or settled? What is the resolution timeline?
Answer: Not determinable from the information provided.
Resolution facts required to produce an actionable timeline
- Whether the case was stayed under
- 21 U.S.C. § 355(j)(5)(B)(iii)
- prior settlement agreements
- Any dismissal without prejudice
- Consent judgments
- Final judgment entry date
- Whether Zydus received FDA approval at a specific time
What is the FDA regulatory impact of 3:23-cv-04152 for Zydus’s ANDA and Azurity’s exclusivity?
Answer: Not determinable from the information provided.
Regulatory linkage facts required for a precise impact assessment
- Which drug/strength/dosage form is at issue
- Whether Zydus’s ANDA is approved, tentatively approved, or blocked
- Whether the 30-month stay applies and its key expiry date
- Whether any carve-outs or noninfringement positions affect stay eligibility
How does AZURITY v. ZYDUS compare with other recent Orange Book Paragraph IV challenges by Zydus?
Answer: Not determinable from the information provided.
What must be observed to support a credible comparison
- Asserted patent estates and recurring targets across cases
- Whether Zydus uses consistent technical defenses (salt/polymorph, process, method-of-use)
- Settlement structures and typical license scopes
What does the patent estate look like for Azurity’s branded product in this dispute?
Answer: Not determinable from the information provided.
Patent estate deliverables typically included in a complete analysis
- Number of Orange Book-listed patents
- Expiration dates by patent family
- Remaining exclusivity windows
- “Risk patents” that are most likely to be struck or to constrain generic entry
What generic entry risks exist for Zydus or other ANDA filers after 3:23-cv-04152?
Answer: Not determinable from the information provided.
Post-litigation risk factors to quantify
- Remaining unasserted patents and unexpired exclusivity
- Whether any patents were held invalid or noninfringed
- Whether Zydus’s design-around could be adopted by other generics
- Whether any settlement includes a covenant not to sue with field limits
Key Takeaways
- The prompt provides only the case caption and docket number. It does not include the underlying docket content needed to extract asserted patents, FDA application linkage, procedural posture, claim theories, invalidity arguments, or resolution.
- A litigation summary with patent-level and regulatory-level precision cannot be produced from the provided information alone.
FAQs
- What court and judge handled AZURITY PHARMACEUTICALS, INC. v. ZYDUS WORLDWIDE DMCC (3:23-cv-04152)?
- Which U.S. patents were asserted in the 3:23-cv-04152 complaint?
- What FDA application (ANDA number) and Paragraph IV certification(s) are tied to 3:23-cv-04152?
- Was the case resolved via settlement, dismissal, or trial, and what was the outcome date?
- What remaining Orange Book patents or exclusivity periods would still block generic entry if 3:23-cv-04152 ends without a full resolution of the full estate?
References
- (No citable sources provided in the prompt.)
